We'll likely get that study......Are you a share holder?
Such a study at this stage is unlikely. Results in the CHF trial can't be ignored and remember they are a different cell type.
As for your previous post . I tend to agree, very interesting but.... Would this be sufficient evidence to support some off label use. This is such a small population randomized controlled trials want happen.
Would this data support EMERGENCY USE in COVID 19?
I would be surprised if these results are not put forward with reasonable ADRS results for EUA.
Not long to find out.
Good luck all.
Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-59
-
- There are more pages in this discussion • 365 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.330B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.22 | $1.15 | $6.344M | 5.404M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8683 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 32999 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |